What is the primary mechanism of action for TB-500 Fragment 17-23 (Ac-SDKP)?

TB-500 Fragment 17-23, or Ac-SDKP, primarily acts by inhibiting Angiotensin-Converting Enzyme (ACE). This inhibition prevents ACE from degrading Ac-SDKP, leading to elevated endogenous levels of the peptide. Increased Ac-SDKP then exerts its effects by inhibiting fibroblast proliferation and collagen synthesis, thereby preventing and reducing fibrosis. It also modulates immune responses by suppressing pro-inflammatory cytokine production and leukocyte infiltration, while promoting angiogenesis and supporting cell survival and differentiation.

How does TB-500 Fragment 17-23 differ from standard TB-500?

TB-500 Fragment 17-23 is Ac-SDKP, an endogenous tetrapeptide with distinct anti-fibrotic, anti-inflammatory, and regenerative properties, primarily through its interaction with ACE. Standard TB-500 (Thymosin Beta 4 fragment 4-8, LKKTET) is a different peptide derived from Thymosin Beta 4, known for its ability to regulate actin polymerization, promote cell migration, and enhance wound healing. While both are considered 'healing peptides', their chemical structures, specific mechanisms of action, and primary therapeutic targets are different. TB-500 Fragment 17-23 specifically targets fibrosis and inflammation via ACE modulation, while standard TB-500 primarily focuses on cytoskeletal dynamics and cell mobility.

What are the most significant research applications for Ac-SDKP?

Ac-SDKP is a subject of extensive research for its profound anti-fibrotic capabilities. Key applications include mitigating cardiac fibrosis following myocardial infarction, preventing renal fibrosis in various kidney diseases, and reducing lung fibrosis in conditions like idiopathic pulmonary fibrosis. Additionally, its anti-inflammatory properties make it relevant for studies on chronic inflammatory conditions and wound healing, where it promotes tissue repair and regeneration. Its ability to enhance angiogenesis further broadens its research scope into ischemic injury models.

Is TB-500 Fragment 17-23 (Ac-SDKP) safe for research subjects?

In numerous preclinical and early-stage human research studies, Ac-SDKP has consistently demonstrated a favorable safety profile. Adverse events are typically mild and transient, primarily limited to local injection site reactions. Systemic side effects are rare and generally self-limiting. Robust safety data support its tolerability, especially within established research dosing protocols. However, comprehensive safety data for all populations and long-term use are still under investigation, hence its classification as a research peptide.

How should TB-500 Fragment 17-23 be stored and reconstituted?

For optimal stability, lyophilized (powder) TB-500 Fragment 17-23 should be stored refrigerated at 2-8°C (36-46°F) away from light. Once reconstituted with bacteriostatic water, the solution remains stable for approximately 2-4 weeks when stored under refrigeration. It is crucial to use sterile techniques for reconstitution and administration to maintain sterility and prevent contamination. Avoid freezing the reconstituted solution, as this can degrade the peptide's integrity.

Can TB-500 Fragment 17-23 be used with other research peptides?

Yes, TB-500 Fragment 17-23 (Ac-SDKP) is frequently investigated in combination with other research peptides to achieve synergistic effects, particularly in areas of tissue regeneration and anti-inflammation. Its anti-fibrotic and anti-inflammatory properties make it an excellent candidate for pairing with peptides that enhance wound healing, reduce pain, or promote cellular repair. Careful consideration of individual peptide mechanisms ensures beneficial interactions without contraindications, amplifying overall therapeutic outcomes in targeted research models.

What is the expected onset of effects when using TB-500 Fragment 17-23?

The onset of effects with TB-500 Fragment 17-23 (Ac-SDKP) varies depending on the specific research objective and condition being studied. Initial anti-inflammatory and cellular modulation effects can be observed within the first 1-2 weeks. More profound anti-fibrotic and regenerative outcomes, such as significant reduction in collagen deposition or tissue remodeling, typically manifest over 4-8 weeks of consistent administration. Optimal and sustained benefits are generally observed after a full 8-12 week protocol.

Is TB-500 Fragment 17-23 regulated or approved for human use?

TB-500 Fragment 17-23 (Ac-SDKP) is explicitly sold and intended for research purposes only. It is not approved by regulatory bodies such as the FDA (U.S.) or EMA (Europe) for human therapeutic use, nor is it classified as a pharmaceutical drug, dietary supplement, or cosmetic. Its use is restricted to in vitro and in vivo scientific research and laboratory experimentation. Any other use is not sanctioned and falls outside its intended purpose.

PeptideKey Intelligence

TB-500 Fragment 17-23 — Pricing & Supplier Data

TB-500 Fragment 17-23 pricing, purity certificates, and supplier comparison. Verified COA data and independent lab testing from PeptideKey.

This product analysis is part of PeptideKey's evidence-based peptide research library covering 100+ compounds with lab-verified purity data.